Table 3.
Quality assessment | № of patients | Effect | Quality | ||||||
---|---|---|---|---|---|---|---|---|---|
№ of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Penicillin | Ceftriaxone | Relative (95 % CI) | |
Neurological symptoms at last reported time point | |||||||||
1 | randomised trials | seriousa | not serious | not serious | very seriousb | 0/11 (0.0 %) | 0/12 (0.0 %) | not estimable | ⨁◯◯◯ VERY LOW |
Neurological symptoms at last reported time point | |||||||||
2 | observational studies | very seriousc | not serious | seriousd | seriouse | 2/55 (3.6 %) | 4/28 (14.3 %) | not pooled | ⨁◯◯◯ VERY LOW |
ano blinding, randomisation and allocation concealment not stated appropriately, selective outcomes reporting cannot be excluded
bvery small sample size, optimal information size not met
cbaseline confounding, selected patients, lack of blinding, interventions insufficiently described
dheterogeneous interventions, interventions not clearly described
esmall sample size, optimal information size not met